China's JW falls most in 4 months on shareholder stake sale plan report

JW (Cayman) Therapeutics Co

29/06/2021 03:15

** Shares of Chinese cell therapy developer JW Cayman
Therapeutics Co Ltd  2126.HK  fall 10.6% to HK$27.70, posting
their biggest intraday percentage decline since Feb. 22
    ** Stock hits the lowest since June 18; the second-most
actively traded by turnover and the seventh-biggest percentage
decliner on the Hong Kong bourse
    ** WuXi AppTec (Hong Kong) Holding has launched a HK$670 mln
($85 mln) block sale in JW Cayman Therapeutics in a
HK$28.50–$29.15/shr range, Refinitiv publication IFR reported
 urn:newsml:reuters.com:*:nIfp1cVnlc
    ** Range represents a 6%–8.1% discount to the pre-deal close
of HK$31 
    ** Up to 23 mln shares, or 5.7% of the existing capital, are
on offer
    ** Hong Kong's healthcare index  .HSCIH  up 0.2%
    ** The Hang Seng China Enterprises Index  .HSCE  slips 0.3%,
and the benchmark index  .HSI  eases 0.4%
    ** The stock of the Shangahi-based JW had surged 17.7% this
year, as of last close 

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))